INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company developing graphene-based technologies, began a strategic collaboration with Microsoft.

The partnership will explore use of agentic artificial intelligence (AI) powered by Microsoft’s cloud and data infrastructure to advance real-time precision neurology and next-gen BCI therapeutics. It will leverage Microsoft’s Azure AI infrastructure, including time-series large language models (LLMs) and data analytics capabilities, to allow INBRAIN’s intelligent neural platform to continuously learn and adapt to individual patient signals.

In an agentic AI approach, AI systems act autonomously based on real-time data. It has the potential to transform monitoring and treatment of neurological disorders, providing closed-loop precision interventions for conditions like Parkinson’s disease, epilepsy, and psychiatric or memory disorders in the future.

INBRAIN co-founder and CEO Carolina Aguilar said the company’s vision is to create the most intelligent, autonomous, and personalized interface between the nervous system and AI.

“By collaborating with Microsoft, we’re combining our precision graphene neural technology with one of the world’s most powerful AI ecosystems,” Aguilar told the press. “This partnership brings us closer to a future where brain-computer interfaces don’t just decode or modulate, but truly understand and respond to the nervous system in real time, making the nervous system, the body OS.”

The company’s neural platform is built on graphene, a single layer of carbon atoms known for conductivity, biocompatibility, and precision. By integrating advanced decoding and modulation with agentic AI, it hopes to build a new class of AI-enabled BCI therapeutics capable of personalized, data-driven modulation of neural circuits in real time.

“This collaboration highlights the next frontier of AI,” said Clare Barclay, president of Enterprise and Industry, EMEA at Microsoft. “INBRAIN’s work sits at the intersection of neuroscience, bioelectronics, and AI, and we are proud to provide the data foundation and computational infrastructure that will help accelerate their mission to improve neurological health worldwide.”

In August, the company shared encouraging interim results from the world’s first-in-human clinical study of its graphene-based BCI technology.